Search the Newsreel

Earnings call transcript: Somnigroup posts Q2 2026 EPS beat as revenue misses

Somnigroup International (NYSE:SGI) Updates FY 2026 Earnings Guidance

Somnigroup International (SGI) Matches Q2 Earnings Estimates

Somnigroup International (SGI) came out with quarterly earnings of $0.58 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.53 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected …

Somnigroup International (SGI) Sets Dividend As Investors Ask If The Valuation Gap Is Real

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Somnigroup International (SGI) has drawn fresh attention after its board declared a third quarter cash dividend of $0.17 per share, payable on September …

Somnigroup (NYSE:SGI) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings

Somnigroup (NYSE:SGI) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings Bedding manufacturer Somnigroup (NYSE:SGI) fell short of the market's revenue expectations in Q2 CY2026, with sales falling 3% year on year to $1.82 billion. Its non-GAAP profit of $0.58 per share was in …

Somnigroup International Inc. Reports Second Quarter 2026 Results

Somnigroup International Inc. (SGI) announced its financial results for the second quarter ended June 30, 2026, reporting an 11% increase in EPS and 9% growth in adjusted EPS. The company saw expanded second-quarter gross margins and record cash flows from operations of $236 million. …

Somnigroup's proposed ~$2.5B all-stock Leggett & Platt deal awaits approvals

Somnigroup International (NYSE: SGI) reported its Q2 2026 financial results, with net sales down 3.0% to $1.82 billion but EPS increasing 10.6% to $0.52 and adjusted EPS up 9.4% to $0.58. The company also announced a quarterly cash dividend of $0.17 per share and …

Somnigroup Announces Third Quarter Cash Dividend

DALLAS, Aug. 6, 2026 /PRNewswire/ -- Somnigroup International Inc. (NYSE: SGI, "Company" or "Somnigroup") today announced that its Board of Directors has declared a third quarter cash dividend on its common stock of $0.17 per share. The dividend is payable on September 3, 2026, …

Somerset Minerals (ASX:SMM) Jumps as Coppermine Assays Extend the High-Grade Copper Story

Somnigroup International (SGI) Earnings Date and Reports 2026 $SGI

Somany Ceramics reschedules Q1FY27 earnings call to 18:00 IST

Somany Ceramics to host investors at Equirus India Growth Summit

Somnigroup International (SGI) Refinances Term Loans Ahead Of Planned Acquisition

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Somnigroup International (NYSE: SGI) amended its credit agreement and refinanced term loans in connection with its anticipated acquisition of Leggett & Platt. The amended facilities …

Axsome Therapeutics (AXSM) insider plans 45,004-share cashless option sale

Axsome Therapeutics insider Herriot Tabuteau has filed a Form 144 indicating an intention to sell up to 45,004 shares of common stock through Goldman Sachs & Co. LLC, with an approximate sale date of August 5, 2026. The shares were originally acquired as compensation …

Somany Ceramics Schedules Q1 FY26-27 Earnings Call for August 12

Axsome Therapeutics Inc (AXSM) News, Articles, Events & Latest Updates

This article provides a compilation of recent news, articles, and updates related to Axsome Therapeutics Inc (AXSM), focusing on its upcoming Q2 earnings, FDA approvals, and ongoing clinical trials. It also includes several Zacks reports placing AXSM on a "Strong Sell" list. Additionally, it …

Is Axsome Therapeutics (AXSM) Trading Profitability for Pipeline Expansion As Revenue Outpaces Earnings?

Axsome Therapeutics (AXSM) is projected to report higher Q2 2026 revenue but lower year-over-year earnings, leading to investor scrutiny regarding its profitability amidst pipeline expansion. The company's investment narrative centers on its CNS franchise eventually translating rising revenues into sustainable profitability, with an FDA …

Somnigroup to Post Q2 Earnings: What's in Store for the Stock?

Somnigroup International Inc. (SGI) is set to report its second-quarter 2026 earnings on August 6, 2026, with expectations for bottom and top-line growth. Analysts project earnings of 58 cents per share and revenues of $1.9 billion, driven by innovation, direct-to-consumer sales, and market share …

Why Blossom Gold Inc. stock is rising today

Axsome Therapeutics (NASDAQ:AXSM) Stock Price Down 4% After Analyst Downgrade

Axsome Therapeutics (NASDAQ:AXSM) shares dropped 4% after Mizuho lowered its price target from $310 to $306, while still maintaining an "outperform" rating. Despite missing adjusted earnings expectations with a loss of $1.26 per share, the company reported a 57.4% year-over-year revenue increase to $191.2 …

Axsome Therapeutics, Inc. (AXSM): Investor Outlook on a Biotech Stock with a 29% Potential Upside

Axsome Therapeutics (AXSM) is a biotech company focused on CNS disorders with a market capitalization of $11.22 billion. Despite negative EPS and ROE, the company has strong analyst ratings, an average target price suggesting a 29.51% upside, and robust revenue growth of 57.40%. Its …

Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for

Axsome Therapeutics (AXSM) to Announce Earnings on Monday

Axsome Therapeutics (NASDAQ: AXSM) is scheduled to announce its Q2 2026 earnings before the market opens on Monday, August 10th. Analysts anticipate a loss of $0.8921 per share and revenue of $221.1 million. Despite a previous EPS miss, revenue increased by 57.4% year-over-year, and …

Somerset Minerals Uncovers Widespread High-Grade Copper at Canadian Coppermine Project

Axsome Therapeutics Inc (0HKF) Q3 2025 Earnings Report - Results, Call & Slides

Axsome Therapeutics (0HKF) released its Q3 2025 earnings report, missing consensus EPS estimates with an actual EPS of -$0.94 against an expected -$0.86. However, the company beat revenue expectations, reporting $170.99M against an expected $162.67M, marking a significant 63.22% year-over-year revenue growth. The earnings …

Axsome Therapeutics, Inc. $AXSM Stock Holdings Lessened by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company reduced its stake in Axsome Therapeutics (NASDAQ:AXSM) by 12.5% in the first quarter, selling 16,791 shares. Despite this, institutional investors collectively own 81.49% of the company, with many major funds increasing their positions. Axsome Therapeutics reported revenue of $191.2 …

Sei Investments Co. Buys 22,464 Shares of Axsome Therapeutics, Inc. $AXSM

Sei Investments Co. significantly increased its stake in Axsome Therapeutics, Inc. by 47.2% in the first quarter, acquiring an additional 22,464 shares, bringing its total to 70,064 shares valued at $11.8 million. This move is part of broader institutional interest, with hedge funds and …

Is It Smart To Buy Somany Ceramics Limited (NSE:SOMANYCERA) Before It Goes Ex-Dividend?

Mizuho Trims Price Target on Axsome Therapeutics to $306 From $310, Keeps Outperform Rating

Mizuho has adjusted its price target for Axsome Therapeutics (AXSM) to $306 from $310, while maintaining an Outperform rating on the stock. This revision comes as part of their ongoing analysis of the biopharmaceutical company.

Mizuho Issues Pessimistic Forecast for Axsome Therapeutics (NASDAQ:AXSM) Stock Price

Mizuho lowered its price target for Axsome Therapeutics (NASDAQ:AXSM) from $310 to $306, while maintaining an "outperform" rating, indicating a potential 40% upside. This comes after the company reported a quarterly loss of $1.26 per share, missing expectations, despite a 57.4% year-over-year revenue increase …

Soma Textiles Releases Unaudited Q1 FY27 Results with Auditor Review

Soma Textiles net profit drops 44% QoQ to ₹2.76 crore in Q1FY27

Soma Textiles & Industries Posts ₹276 Lakh Net Profit for Q1 FY27; Revenue From Operations Surges YoY to ₹2,839 Lakhs

Soma Textiles & Industries pivots to highway construction; Q1 revenue jumps 1385% to ₹28.39 crore

Axsome Therapeutics Inc (AXSM) Financial Health: Profitability & Balance Sheet Analysis

Axsome Therapeutics Inc (AXSM) has a stable financial status and high operating efficiency, with its financial score at 8.07, ranking 74 out of 155 in the Pharmaceuticals industry. The company reported a latest quarterly revenue of $191.20M, marking a 57.42% year-over-year increase, and an …

Axsome Therapeutics Inc (AXSM) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Axsome Therapeutics Inc (AXSM), detailing its price momentum score of 3.33, ranking 111 out of 155 in the Pharmaceuticals industry. It highlights the stock's current trading range between resistance at $251.09 and support at $219.70, suggesting suitability …